Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure—Assessment of Reduction in Mortality and morbidity programme

Aims Ageing may affect drug efficacy and safety in patients with heart failure (HF). The Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme offered an opportunity to study the relationship between increasing age and the efficacy and safety of treatment...

Full description

Saved in:
Bibliographic Details
Published in:European heart journal 2008-12, Vol.29 (24), p.3022-3028
Main Authors: Cohen-Solal, Alain, McMurray, John J.V., Swedberg, Karl, Pfeffer, Marc A., Puu, Margareta, Solomon, Scott D., Michelson, Eric L., Yusuf, Salim, Granger, Christopher B.
Format: Article
Language:English
Subjects:
Adult
Adverse events
Age
Age Distribution
Age Factors
Aged
Aged, 80 and over
Angiotensin II Type 1 Receptor Blockers - adverse effects
Angiotensin II Type 1 Receptor Blockers - therapeutic use
Benzimidazoles - adverse effects
Benzimidazoles - therapeutic use
Biological and medical sciences
Candesartan
Cardiology. Vascular system
Chronic Disease
Dose
Female
Heart
Heart failure
Heart Failure - drug therapy
Heart Failure - mortality
Heart Failure - physiopathology
Heart failure, cardiogenic pulmonary edema, cardiac enlargement
Hospitalization
Hospitalization - statistics & numerical data
Humans
Male
Medical sciences
Middle Aged
Mortality
Practice Guidelines as Topic
Proportional Hazards Models
Risk Assessment
Stroke Volume - drug effects
Tetrazoles - adverse effects
Tetrazoles - therapeutic use
Treatment Outcome
Ventricular Dysfunction, Left - drug therapy
Ventricular Dysfunction, Left - mortality
Ventricular Dysfunction, Left - physiopathology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aims Ageing may affect drug efficacy and safety in patients with heart failure (HF). The Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme offered an opportunity to study the relationship between increasing age and the efficacy and safety of treatment in an uniquely broad spectrum of patients with symptomatic HF and either reduced or preserved left ventricular ejection fraction. Methods and results A total of 7599 patients in NYHA Class II–IV HF were randomized to candesartan (target dose 32 mg once daily, mean dose 24 mg) or placebo, including 3169 patients age >70 years. Mean follow-up was 37.7 months. The proportional hazards model was used to estimate the treatment effect on efficacy and safety within five age groups:
ISSN:0195-668X
1522-9645
DOI:10.1093/eurheartj/ehn476